abstract: Editorial: Whole-Genome Sequencing, April 20, 2011 JAMA

Note: full access requires subscription ($$)

Whole-Genome Sequencing

Since this article does not have an abstract, we have provided the first 150 words of the full text.

KEYWORDS:
• EARLY DIAGNOSIS,
• GENETIC PREDISPOSITION TO DISEASE,
• GENOME, HUMAN,
• LEUKEMIA, MYELOID, ACUTE,
• LEUKEMIA, PROMYELOCYTIC, ACUTE,
• MUTATION,
• NEOPLASMS,
• ONCOGENE PROTEINS, FUSION,
• ONCOGENES,
• SEQUENCE ANALYSIS, DNA,
• TIME FACTORS,
• TP53 GENES,
• TP53 PROTEIN, HUMAN.

The past 60 years have witnessed remarkable progress in genetics and genomics from the description of the DNA double helix by Watson and Crick ¹ to the release of the first draft sequence of the human genome in 2001 ^{2, 3} and the successful completion of the human genome project in 2003. ⁴ From that time, there has been increasing hope and expectation that, as soon as the cost of sequencing the whole genome could become affordable, the promise of personalized medicine would be fulfilled.

No field of medicine has benefited more from advances in genomics and the application of genetic testing than oncology. These advances have had a substantial influence on cancer risk assessment, determination of prognosis, and choice of treatment. Clinical applications of novel genetic tools include sequencing and analysis of germline genomic rearrangements at key cancer genes like BRCA1, BRCA2, and TP53 ⁵; …

NCI Cancer Bulletin: Whole-Genome Sequencing Improves Cancer Diagnoses (including some good links eg Li-Fraumeni Syndrome, BRCA, Editorial)

Whole-Genome Sequencing Improves Cancer Diagnoses

Although whole-genome sequencing is not yet ready for routine clinical use, two studies show how the approach could improve the diagnosis and, potentially, the treatment of cancer. The reports, in the April 20 Journal of the American Medical Association, describe how researchers at Washington University School of Medicine in St. Louis and their colleagues used whole-genome sequencing to investigate the cases of two patients.
The first study focused on a 42-year-old woman who died from leukemia that was probably related to previous treatment for breast and ovarian cancers. The woman did not have a known family history of cancer, and tests for mutations in the breast cancer-associated genes BRCA1 and BRCA2 were negative. But a comparison of the genomes of her cancer cells and normal cells revealed a novel mutation in the TP53 gene that altered the function of the encoded protein. TP53 gene mutations have been implicated in a number of cancers, including some early-onset breast and ovarian cancers, as well as Li-Fraumeni syndrome.
The TP53 mutation does not appear to have been inherited from one of the patient’s parents. But because the mutation was seen in both normal and cancer cells, it had to have occurred very early in the patient’s life, possibly at conception. Thus, the mutation could have been present in her germline DNA and been passed on to her children, the researchers noted.
As specified by the study protocol, the researchers contacted the woman’s primary care physician, who then discussed the issue with the patient’s family members and encouraged them to seek genetic counseling. “Even though the patient died, her contribution to this study yielded new knowledge that might one day save the lives of her children,” study co-author Dan Koboldt of the Genome Institute at Washington University wrote in a post about the studies on his blog, MassGenomics.
The second study involved a 39-year-old woman with a form of acute myeloid leukemia (AML). A comparison of DNA from her tumor and normal cells revealed a fusion of two genes in her blood cells that was not detected through routine cytogenetic testing. The presence of this gene fusion is associated with good outcomes after chemotherapy. Consequently, the patient’s doctors recommended chemotherapy rather than stem cell transplantation, the treatment that had been indicated by the standard diagnostic testing results.
At the time of publication, the woman had been in remission for 15 months. The sequencing, analysis, and validation of the fusion gene were completed in just 7 weeks, which was quick enough that doctors could use the information to choose the most effective treatment for the patient, the researchers noted.
“These cases of personalized genomic medicine are just some of the first examples of what will likely be commonplace in the near future,” wrote the authors of an accompanying editorial.
“Clearly, the technology will no longer be the major impediment to widespread clinical use of these tools, and the main challenges will soon move to the clinical implementation and interpretation of genomic data,” the authors added.

full free access: Levothyroxine dose & risk of fractures in older adults: nested case-control study -- Women's College Hospital Toronto study (hypothyroidism)

Note:
the study excluded thyroid cancer survivors but a quick scan does not indicate a search of the database/inclusion/exclusion of a prior/present history of other cancers with the exception of reference #44 prostate cancer

(eg. pre-menopausal longterm cancer survivours/longterm use of hypothydroism medications - comments/opinions welcome on this issue)

Also known as:  

Brand names
Eltroxin
Estre
Euthyrox
Levo-T
Levotabs
Levothroid
Levoxyl
Novothyrox
Synthroid
Thyrox
Unithroid  

Brand names of combination products
Thyrolar 1 (containing Thyroxine and Triiodothyronine) Thyrolar 1/2 (containing Thyroxine and Triiodothyronine) Thyrolar 1/4 (containing Thyroxine and Triiodothyronine) Thyrolar 2 (containing Thyroxine and Triiodothyronine) Thyrolar 3 (containing Thyroxine and Triiodothyronine)
 ```````````````````````````````````````````

Study cohort

Tory Silence On Medicare Pledge “Deafening” - Health Care Pledge Supported By All Parties, But One (Harper) note: finance minister Jim Flaherty a 'no response'

Tory Silence On Medicare Pledge “Deafening”
Health Care Pledge Supported By All Parties, But One

TORONTO ‐ Stephen Harper’s decision to refuse even the most basic commitment to Medicare has caused surprise and concern among Canadians who care about our health care system. Hundreds of local candidates representing the Liberal, New Democratic and Green Parties, and all three of their National Leaders, have given their support to the Health Care Protection Pledge, a commitment to sustain Medicare past the 2014 Health Accord negotiations. Stephen Harper is the only national leader who has chosen not to express support for our health care system, and all but two Conservative candidates have followed his lead, almost universally refusing to make a commitment to Medicare....cont'd

Canadian Doctors for Medicare - deadline to sign pledge to support Canadian health care system (re: federal election)

Sample Email To Federal Candidates

Dear ,
I am writing to ask that you make a commitment to our health care system and sign the Canadian Doctors for Medicare Health Care Protection Pledge.

The pledge was emailed to you last week and simply asks you to offer your commitment to protect our health care system. That commitment involves:

 Sustaining the Canada Health Act with all its protections and all five principles now and after the 2014 Health Accord and enforce it across Canada.
 Continuing to fund health care through Federal transfer payments tied to compliance with the Canada Health Act.

Please confirm your commitment to our health care system by signing the pledge and sending it to Canadian Doctors for Medicare by April 29th, 2011.

Canadian Doctors for Medicare will be publishing a list of candidates who signed, and who did not sign the pledge before voting day.

If you haven’t received the pledge, you can contact Canadian Doctors for Medicare at info@canadiandoctorsformedicare.ca or download a pledge form from their website www.canadiandoctorsformedicare.ca.
Sincerely,

....................................................

2011 Federal Candidates (separated by province/territory)
Alberta: AB_Federal_Candidates.pdf
British Columbia: BC_Federal_Candidates.pdf
Manitoba: MB_Federal_Candidates.pdf
New Brunswick: NB_Federal_Candidates.pdf
Newfoundland: NL_Federal_Candidates.pdf
Northwest Territories: NWT_Federal_Candidates.pdf
Nova Scotia: NS_Federal_Candidates.pdf
Nunavut: NU_Federal_Candidates.pdf
Prince Edward Island: PE_Federal_Candidates.pdf
Saskatchewan: SK_Federal_Candidates.pdf
Yukon: YK_Federal_Candidates.pdf

Target Ovarian Cancer Calls On DOH To Launch National Symptom Awareness Campaign As New NICE Guidance Stresses Importance Of Early Diagnosis, UK

Note: media story regarding new NICE guidelines for ovarian cancer

IMEDEX: Interactive Case: Ovarian Cancer: Front-Line Therapy in Patient with Inadequate Debulking Surgery

Note:  registration required (free), discusses Japanese trial with weekly Taxol and increased overall survival, GOG 262 ((see arms 1 & 2)  etc...

Interactive Case: Ovarian Cancer: Front-Line Therapy in Patient with Inadequate Debulking Surgery VIEW ACTIVITY Overview: Dr Bradley Monk very eloquently describes a case of newly diagnosed advanced ovarian cancer and reinforces the importance of debulking surgery and combination chemotherapy. Various therapeutic options and recent clinical trial data are discussed. Topics: • Small and large volume residual disease and treatment decision making • Standards and clinical trials • Role of antiangiogenic agents in ovarian cancer management

4/26/2011: full free access: Recent progress in the diagnosis and treatment of ovarian cancer -- Jelovac and Armstrong, 10.3322/caac.20113 -- CA: A Cancer Journal for Clinicians

Published online before print April 26, 2011, no registration req'd

April 2011: NICE Guidelines - Ovarian cancer: the recognition and initial management of ovarian cancer

The recognition and initial management of ovarian cancer

Description

This clinical guideline offers evidence-based advice on the care and early treatment of women with suspected or confirmed ovarian cancer.
This guidance updates and replaces recommendation 1.7.4 in Referral guidelines for suspected cancer (NICE clinical guideline 27; published 2005).

Guidance documents

• Full guideline PDF format  | MS Word format
• NICE guideline PDF format  | MS Word format
• Quick reference guide PDF format
• NICE guidance written for patients and carers PDF format  | MS Word format
• CG122 Ovarian cancer: guidance (web format)

Implementing this guidance

• Baseline assessment tool
• Clinical audit tool
• Clinical case scenarios
• Costing statement
• Slide set

• CG122 Ovarian cancer: GP podcast
• CG122 Ovarian cancer: SLR podcast

Other information

• Background information

About this guidance

Clinical guidelines CG122

Issued: April 2011
How this guidance was produced

Order printed copies of this guidance

This page was last updated: 27 April 2011

NICE Unable To Recommend Ovarian Cancer Drug In Final Guidance Due To Lack Of Appropriate Evidence (trabectedin (Yondelis)

reports available on line: Charity Intelligence Canada - Home

To receive a copy of our reports via email, contact info@charityintelligence.ca

website: Charity Intelligence Canada

Note: website includes background and financials:

Audited Financial Statements - Year Ending June 30, 2010

Audited Financial Statements - Year Ending June 30, 2009
Audited Financial Statements - Year Ending June 30, 2008

Also  »  Recommended Charities 2010

CTV Winnipeg- Too many deadly cancers go underfunded: report - CTV News

Charity Intelligence notes there are more than 200 forms of cancer, but the 10 forms that represent 70 per cent of Canadian cancer cases, deaths, potential years of life lost, and prevalence include:

• lung
• colorectal
• breast
• pancreatic
• non-Hodgkin lymphoma
• brain
• leukemia
• prostate
• ovarian
• stomach cancers

It also includes sarcoma, because it was the form of cancer that affected Terry Fox, who changed the face of cancer charity donations forever.

EvidenceUpdates - abstract/commentaries: Colonic stenting versus emergency surgery for acute left-sided malignant colonic obstruction: a multicentre r

 Note: this study was originally published in The Lancet and involved patients in 25 hospitals; the study pertained to left-sided colorectal cancers however may be appropriate/of interest to other cancer patient populations; commentaries are included from a variety of professions including gastroenterologist, oncologists...

 ------------------------------------------------------------------------------
BACKGROUND: Colonic stenting as a bridge to elective surgery is an alternative for emergency surgery in patients with acute malignant colonic obstruction, but its benefits are uncertain. We aimed to establish whether colonic stenting has better health outcomes than does emergency surgery.

Health-evidence Canada - website

Note: the benefit of this site is the combined link/abstract information plus professional commentaries; registration is free

About Us

This web site was originally created with funds from the Canadian Institutes of Health Research and is supported today in part by the National Collaborating Centre for Aboriginal Health (NCCAH), National Collaborating Centre for Environmental Health (NCCEH), National Collaborating Centre for Healthy Public Policy (NCCHPP), National Collaborating Centre for Infectious Diseases (NCCID), National Collaborating Centre for Methods and Tools (NCCMT), and the City of Hamilton Public Health Services Division.
The initial project, funded by the Canadian Institutes of Health Research, was conducted by Dr. Maureen Dobbins, Associate Professor, McMaster University (Ontario, Canada) to promote an ongoing environment of collaboration between the research community and the decision-making and practice setting. This site continues to achieve this goal with the City of Hamilton Public Health Services Division, by actively collaborating in ongoing research initiatives.
The ultimate goal of this site is to facilitate the adoption and implementation of effective policies/programs/interventions at the local and regional public health decision making levels across Canada.

To develop this web site, the research team worked to:

1. Identify, appraise, and make available methodologically-sound reviews of health promotion and public health interventions published from 1985 to the present
2. Conduct a comprehensive literature review and consult with 54 key practitioners in Canada to learn about how decisions are being made in these respective organizations, and to determine the best ways to summarize the results of reviews and disseminate findings
3. Consult with graphic design and marketing experts to assist with the preparation and marketing of dissemination material
4. Conduct 9 focus groups with practitioners to obtain their feedback on the dissemination strategy that was pilot tested in the fall of 2002 with Canadian decision makers, medical officers of health, public health managers and directors, health promotion mangers, and health policy makers at Canadian provincial and federal levels. A 2-page summary statements format was developed to synthesize the results of well-done systematic reviews and this summary format is being used to present the key findings of select reviews within the health-evidence.ca registry.
5. Identify public health and health promotion interventions that have not yet been systematically reviewed and begin to notify relevant funders of these gaps.
6. Evaluate knowledge transfer and exchange efforts on an ongoing basis and continue to work towards a national strategy for public health in Canada.

The Associated Press: Push to spur more drugs for deadly rare diseases

"There are treatments for just 200 of the roughly 7,000 rare diseases, illnesses that affect fewer than 200,000 people, often far, far fewer. Yet add those diseases together, and more than 20 million Americans have one." "A new International Rare Diseases Research Consortium is pushing for at least 200 more treatments by 2020, in part by pooling the work of far-flung scientists and families. Rather than starting from scratch, the Food and Drug Administration is pointing the way for manufacturers to "repurpose" old drugs for new use against rare diseases, publishing a list of those deemed particularly promising."

medical news: New Class of Cancer Drugs Could Work in Colon Cancers with Genetic Mutation (PARP inhibitors/MRE11 gene/Lynch Synrome))

15% of colorectal cancers have mutation that responds to PARP inhibitors

Newswise — ANN ARBOR, Mich. — A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan Comprehensive Cancer Center finds.

Working in cell lines from colorectal cancer patients, researchers found that a new class of drugs called PARP inhibitors worked against tumors with mutations in the MRE11 gene.

ongoing: Safety/Efficacy Study of a Drug to Reduce Thrombocytopenia in Patients Receiving Chemotherapy for Ovarian, FT or PC (Angiotensin 1-7)

Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - Full Text View - ClinicalTrials.gov

Note: not yet recruiting

Estimated Enrollment:	50
Study Start Date:	April 2011
Estimated Study Completion Date:	March 2013

April 2011 index: Journal of Geriatric Oncology - Current Issue

example (abstract):

Volume 2, Issue 2, Pages 99-104 (April 2011)
Clinical aspects of the management of elderly women diagnosed with gynecologic malignancies: Treatment decisions and choices
The number of elderly women diagnosed with gynecologic cancer is increasing. This paper reviews the current trends in the management of elderly gynecologic cancer patients. Our goal is to identify critical issues that must be weighed when selecting treatment for elderly gynecologic oncology patients. As individuals continue to achieve longer lifespans, and the population of elderly women continues to grow, gynecologic oncologists will face new challenges regarding treatment. Due to minimal inclusion in randomized controlled trials and the influence of selection bias in many of the current studies, little evidence-based data is available regarding the most effective treatment options for this population. It is therefore unclear whether treatment should differ from that offered to younger populations, and if so under what circumstances. As of yet, there are no validated measures by which to determine tolerability and success of aggressive therapies for this population. Ultimately, each patient must be evaluated individually with regards to risk factors and prognosis, and therapy should not be withheld from elderly individuals solely on the basis of age alone.

Commentary: Accountable Care Organizations and Community Empowerment - — JAMA

Less apparent to the public during this period of historic change are the struggles occurring in US board rooms among hospital groups, specialty physicians, and primary care clinicians—debating quietly but intensely over how to form these ACOs, how to be accountable for care delivery, and how to divide anticipated savings derived from ACOs. However, in most of these settings, important constituencies—middle class and other working patients whose health and welfare are at stake—are not included in the discussions.......................The high and accelerating increases in the cost of health care and the limited roles of patients in decision making central to health and health care delivery are too real to ignore. Decision making by distal proxies such as elected legislators may no longer be enough to address the United States' mounting problems with health care, outcomes, and costs.

abstract: Health Outcomes After Stopping Conjugated Equine Estrogens Among Postmenopausal Women With Prior Hysterectomy — JAMA

Health Outcomes After Stopping Conjugated Equine Estrogens Among Postmenopausal Women With Prior Hysterectomy

A Randomized Controlled Trial

Abstract

Context 

The Women's Health Initiative Estrogen-Alone Trial was stopped early after a mean of 7.1 years of follow-up because of an increased risk of stroke and little likelihood of altering the balance of risk to benefit by the planned trial termination date. Postintervention health outcomes have not been reported. 

Objective 

To examine health outcomes associated with randomization to treatment with conjugated equine estrogens (CEE) among women with prior hysterectomy after a mean of 10.7 years of follow-up through August 2009. 

Design, Setting, and Participants 

The intervention phase was a double-blind, placebo-controlled, randomized clinical trial of 0.625 mg/d of CEE compared with placebo in 10 739 US postmenopausal women aged 50 to 79 years with prior hysterectomy. Follow-up continued after the planned trial completion date among 7645 surviving participants (78%) who provided written consent. 

Main Outcome Measures 

The primary outcomes were coronary heart disease (CHD) and invasive breast cancer. A global index of risks and benefits included these primary outcomes plus stroke, pulmonary embolism, colorectal cancer, hip fracture, and death. 

Results 

The postintervention risk (annualized rate) for CHD among women assigned to CEE was 0.64% compared with 0.67% in the placebo group (hazard ratio [HR], 0.97; 95% confidence interval [CI], 0.75-1.25), 0.26% vs 0.34%, respectively, for breast cancer (HR, 0.75; 95% CI, 0.51-1.09), and 1.47% vs 1.48%, respectively, for total mortality (HR, 1.00; 95% CI, 0.84-1.18). The risk of stroke was no longer elevated during the postintervention follow-up period and was 0.36% among women receiving CEE compared with 0.41% in the placebo group (HR, 0.89; 95% CI, 0.64-1.24), the risk of deep vein thrombosis was lower at 0.17% vs 0.27%, respectively (HR, 0.63; 95% CI, 0.41-0.98), and the risk of hip fracture did not differ significantly and was 0.36% vs 0.28%, respectively (HR, 1.27; 95% CI, 0.88-1.82). Over the entire follow-up, lower breast cancer incidence in the CEE group persisted and was 0.27% compared with 0.35% in the placebo group (HR, 0.77; 95% CI, 0.62-0.95). Health outcomes were more favorable for younger compared with older women for CHD (P = .05 for interaction), total myocardial infarction (P = .007 for interaction), colorectal cancer (P = .04 for interaction), total mortality (P = .04 for interaction), and global index of chronic diseases (P = .009 for interaction). 

Conclusions 

Among postmenopausal women with prior hysterectomy followed up for 10.7 years, CEE use for a median of 5.9 years was not associated with an increased or decreased risk of CHD, deep vein thrombosis, stroke, hip fracture, colorectal cancer, or total mortality. 

A decreased risk of breast cancer persisted. 

abstract: Familial Cancer - Mutation deep within an intron of MSH2 causes Lynch syndrome

"...thus highlighting the need for more extensive sequencing approaches in families where routine procedures fail to find a mutation."

abstract: Familial Cancer, A putative Lynch syndrome family carrying MSH2 and MSH6 variants of uncertain significance—functional analysis reveals the pathological one

Abstract

Inherited pathogenic mutations in the mismatch repair (MMR) genes, MSH2, MLH1, MSH6, and PMS2 predispose to Lynch syndrome (LS). However, the finding of a variant or variants of uncertain significance (VUS) in affected family members complicates the risk assessment. Here, we describe a putative LS family carrying VUS in both MSH2 (c.2768T>A, p.Val923Glu) and MSH6 (c.3563G>A, p.Ser1188Asn). Two colorectal cancer (CRC) patients were studied for mutations and identified as carriers of both variants. In spite of a relatively high mean age of cancer onset (59.5 years) in the family, many CRC patients and the tumor pathological data suggested that the missense variation in MSH2, the more common susceptibility gene in LS, would be the predisposing alteration. However, MSH2 VUS was surprisingly found to be MMR proficient in an in vitro MMR assay and a tolerant alteration in silico. By supplying evidence that instead of MSH2 p.Val923Glu the MSH6 p.Ser1188Asn variant is completely MMR-deficient, the present study confirms the previous findings, and suggests that MSH6 (c.3563G>A, p.Ser1188Asn) is the pathogenic mutation in the family. Moreover, our results strongly support the strategy to functionally assess all identified VUS before predictive gene testing and genetic counseling are offered to a family.

LOVD - An Open Source DNA variation database system (eg. genetic testing/unknown clinicial variant/s)

LOVD stands for Leiden Open (source) Variation Database.
LOVD's purpose : To provide a flexible, freely available tool for Gene-centered collection and display of DNA variations.

Mutalyzer

LOVD features integration with the Mutalyzer sequence variant nomenclature checker, allowing for direct nomenclature checking of sequence variants during the submission process.

If you are looking for a specific gene database, please check the list of gene variant databases at the HGVS site, in our list of LSDBs, or in the list of registered LOVD installations.

abstract: Calculator for ovarian carcinoma subtype prediction : Modern Pathology

Abstract:

With the emerging evidence that the five major ovarian carcinoma subtypes (high-grade serous, clear cell, endometrioid, mucinous, and low-grade serous) are distinct disease entities, management of ovarian carcinoma will become subtype specific in the future.

In an effort to improve diagnostic accuracy, we set out to determine if an immunohistochemical panel of molecular markers could reproduce consensus subtype assignment.

Immunohistochemical expression of 22 biomarkers were examined on tissue microarrays constructed from 322 archival ovarian carcinoma samples from the British Columbia Cancer Agency archives, for the period between 1984 and 2000, and an independent set of 242 cases of ovarian carcinoma from the Gynaecologic Tissue Bank at Vancouver General Hospital from 2001 to 2008. Nominal logistic regression was used to produce a subtype prediction model for each of these sets of cases. These models were then cross-validated against the other cohort, and then both models were further validated in an independent cohort of 81 ovarian carcinoma samples from five different centers.

Starting with data for 22 markers, full model fit, backwards, nominal logistic regression identified the same nine markers (CDKN2A, DKK1, HNF1B, MDM2, PGR, TFF3, TP53, VIM, WT1) as being most predictive of ovarian carcinoma subtype in both the archival and tumor bank cohorts. These models were able to predict subtype in the respective cohort in which they were developed with a high degree of sensitivity and specificity (κ statistics of 0.88±0.02 and 0.86±0.04, respectively).

When the models were cross-validated (ie using the model developed in one case series to predict subtype in the other series), the prediction equation's performances were reduced (κ statistics of 0.70±0.04 and 0.61±0.04, respectively) due to differences in frequency of expression of some biomarkers in the two case series. Both models were then validated on the independent series of 81 cases, with very good to excellent ability to predict subtype (κ=0.85±0.06 and 0.78±0.07, respectively).

A nine-marker immunohistochemical maker panel can be used to objectively support classification into one of the five major subtypes of ovarian carcinoma.

Observations: Electronic health records face human hurdles more than technological ones

abstract: Early detection of ovarian cancer - Early detection of ovarian cancer† If only we had a “Pap smear” for this disease

Abstract:

Primary care physicians are recognizing the symptoms of ovarian cancer and ordering the appropriate diagnostic tests. On the basis of the diverse behavior of epithelial cancers, the goal of screening technology should shift from diagnosing early stage to diagnosing low-volume disease.

abstract: Symptom burden in cancer survivors 1 year after diagnosis Cancer

CONCLUSIONS:

More than 1 in 4 cancer survivors had high symptom burden 1 year postdiagnosis, even after treatment termination. These results indicate a need for continued symptom monitoring and management in early post-treatment survivorship, especially for the underserved.

abstract: Cancer-related chronic pain - Cancer

CONCLUSIONS:

The authors extend the literature by showing that 20% of diverse cancer survivors had cancer-related CP, and 43% had experienced pain since diagnosis, revealing racial and sex disparities in cancer-related CP's incidence and impact on QOL. Having pain was related to poorer QOL in several domains and was more frequently experienced by women. Although black race was not related to pain prevalence, it was related to greater severity. This study reveals an unaddressed cancer survivorship research, clinical, and policy issue

press release U.S. - FDA Grants Orphan Drug Designation for Nektar's Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer (NKTR-102)

Nektar Therapeutics (Nasdaq: NKTR) today announced that the company's oncology drug candidate, NKTR-102, has been granted orphan drug status for the treatment of women with ovarian cancer by the U.S. Food and Drug Administration (FDA).




Nektar has a Phase 2 study ongoing for NKTR-102 that is enrolling approximately 125 patients with platinum-resistant ovarian cancer whose disease has progressed following treatment with pegylated liposomal doxorubicin (PLD) therapy.  In addition, Phase 3 planning is also underway for NKTR-102 in ovarian cancer.  For more information about clinical trials for NKTR-102, please visit the Nektar Therapeutics website.


NKTR-102 is an investigational agent and is not approved by the FDA, the European Medicines Agency (EMA) or other Health Authorities.

abstract: Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer (inhibitors)

PURPOSE:
Patupilone is a novel microtubule-targeting cytotoxic agent with potential interaction with CYP3A4/CYP2C19 enzymes. Midazolam and omeprazole are primarily metabolized by CYP3A4 and CYP2C19, respectively. We evaluated the inhibitory effects of patupilone on the CYP3A4/CYP2C19 pathways.

METHODS:
This study had 2 parts: in an initial core phase, patients were randomly assigned to receive midazolam 4 mg or omeprazole 40 mg PO (days 1 and 29) and patupilone 10 mg/m(2) IV (days 8 and 29). Patients without progression continued patupilone every 3 weeks until disease progression or unacceptable toxicity (extension phase).

full free access: Docetaxel Distribution Following Intraperitoneal Administration in Mice Journal of Pharmacy & Pharmaceutical Sciences (technical)

Note: in mice (research); technical

abstract: Role of Minimally Invasive Surgery in Staging of Ovarian Cancer

Abstract

OPINION STATEMENT:
Since the introduction of laparoscopy and robotic surgery in gynecologic practice in the last several decades, use of these minimally invasive surgical techniques has increased dramatically. The role of minimally invasive surgical techniques continues to expand because they offer reduced intraoperative and postoperative complications, less intraoperative blood loss, and a shorter postoperative recovery. Despite initial concerns about the use of minimally invasive surgery in gynecologic oncology, this approach has been shown to be safe and effective in the management of uterine and cervical cancer, and minimally invasive surgical management of these malignancies is now commonplace. Concerns remain regarding the use of minimally invasive surgery for the staging and management of ovarian cancer, including concerns regarding the adequacy of abdominal exploration and staging with minimally invasive approaches compared to traditional laparotomy and the risks and implications of intra-operative tumor cyst rupture and port-site metastases. However, several case series, retrospective reviews, and case-control studies have demonstrated that minimally invasive surgery is both safe and effective for the staging of borderline ovarian tumors and early-stage epithelial ovarian cancer when performed by a trained gynecologic oncologist. Data to support the role of minimally invasive surgery for advanced epithelial ovarian cancer are scant and use of minimally invasive surgery in this setting is not recommended.

abstract: Case studies in the diagnosis and management of Peutz-Jeghers Syndrome (PJS) (ovarian sex cord tumors)

Abstract

Peutz-Jeghers syndrome (PJS) is a rare genetic disorder characterized by melanotic macules, gastrointestinal polyps and increased cancer risks. We discuss several common scenarios encountered in the diagnosis and management of PJS patients. If the diagnosis is unclear, all pathological material should be re-evaluated by an expert gastrointestinal pathologist. The PJS discussion email list-serve (patient managed) and the peutz-jeghers.com, geneclinics.org, stk11.com websites are useful resources for patients.

abstract: Breast and Ovarian Cancer: The Forgotten Paternal Contribution

Individuals with a paternal family history were found to have a different, and higher, pattern of risk estimates. No significant difference was seen between the type of referrals sent by general practitioners, oncologists, and gynecologists.

full free access: Phase ii/iii study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: Canada

Note:

1) see Section 2.3 for study criteria (patient enrollment requirements);
2) .... acquisition of tumour specimens both before study therapy is started and after neoadjuvant chemotherapy has been received provides a unique opportunity for a correlative study of differing drug responses within the same patients.

Although the study is led by the ncic ctg, the protocol, the accompanying IP therapy guidelines, and a companion document intended to summarize and promote best practice in the administration of IP therapy are the result of a collaboration between the ncic ctg and the Society of Gynecologic Oncologists of Canada, with international partners in the United Kingdom (National Cancer Research Institute), Spain (Spanish Ovarian Cancer Research Group), and the United States (Southwest Oncology Group).

Abstract: (including full free text access):

abstract: Early Detection of Recurrent Ovarian Cancer in Patients with Low-Level Increases in Serum CA-125 Levels by PET/CT

Abstract

Purpose: Serum CA-125 has been shown to be a sensitive tumor marker of recurrent ovarian cancer. The goal of this study was to evaluate the use of 2-[F-18]fluoro-2-deoxy-d-glucose-positron emission tomography/computed tomography (FDG-PET/CT) in the early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 levels.

abstract: A longitudinal investigation of (PTSD) posttraumatic stress disorder in patients with ovarian cancer

Abstract
INTRODUCTION:
Exposure to the aggressive and life-threatening nature of ovarian cancer and its treatment is potentially traumatic. However, little is known about the occurrence of posttraumatic stress disorder (PTSD) in these patients.

abstract: Ovarian cancer in the elderly: Impact of surgery on morbidity and survival (France)

Note: in this study 'elderly' =  70+ yrs

CONCLUSION:

Elderly ovarian cancer patients undergo less extensive surgery and have lower OS (overall survival) despite similar postoperative morbidity, optimal resection and DFS. OS decrease could be explained by difference in the management of recurrences.

Apr 2011: free full access - Recognition and initial management of ovarian cancer: summary of NICE guidance -- bmj.com

Note: guidelines include Carboplatin alone in high-risk early stage; IP for advanced stage ovarian cancer via clinical trial/s (which brings up the question as to the availability of trials??) Future research What is the relationship between the duration and frequency of symptoms in women with ovarian cancer before diagnosis, and the stage of disease at diagnosis and subsequent survival? What is the optimum threshold on the risk of malignancy index I (RMI I) that should be applied in secondary care to guide the management of women with suspected ovarian cancer? How does computed tomography compare with magnetic resonance imaging in accuracy of staging and prediction of optimal cytoreduction? Answering this will require large, multicentre case-control studies. What are the cost effectiveness and risks of systematic retroperitoneal lymphadenectomy in women whose ovarian cancer seems to be confined to the ovaries? Answering this will require a prospective randomised trial. What is the effectiveness of primary surgery in women with advanced ovarian cancer that cannot be fully excised?

free full access: Calcium supplements with/without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative - bmj.com (including responses)

Abstract/Conclusions:
Calcium supplements with or without vitamin D modestly increase the risk of cardiovascular events, especially myocardial infarction, a finding obscured in the WHI CaD Study by the widespread use of personal calcium supplements. A reassessment of the role of calcium supplements in osteoporosis management is warranted.

excerpt (from full text):

"...An important question that arises is whether co-administered calcium and vitamin D affects cardiovascular risk. The Women’s Health Initiative reported no adverse effect of calcium and vitamin D (1 g calcium/400 IU vitamin D daily) on any cardiovascular end point in their large (n=36 282), seven year, randomised, placebo controlled trial.3 4 However, 54% of the participants were taking personal (non-protocol) calcium supplements at randomisation and 47% were taking personal vitamin D supplements, effectively rendering this trial a comparison of higher dose and lower dose calcium and vitamin D for most of the participants.

Allowing clinical trial participants free access to the intervention being studied is unusual and has the potential to obscure both adverse and beneficial effects..."

press release- (OVA1 test) Vermillion to Host Conference Call to Present Company Update and Review Financial Results May 10th, 2011

BJC - Abstract - Predictors of contralateral breast cancer in BRCA1 and Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers (stage 1/11 breast cancer/mutation carriers)

Purpose:

The objective of this study was to estimate the risk of contralateral breast cancer in BRCA1 and BRCA2 carriers; and measure the extent to which host, family history, and cancer t

Conclusion:

The risk of contralateral breast cancer risk in BRCA mutation carriers declines with the age of diagnosis and increases with the number of first-degree relatives affected with breast cancer. Oophorectomy reduces the risk of contralateral breast cancer in young women with a BRCA mutation.

BJC - Abstract: Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis

Results:

  The five studies included 47 325 SLE patients (42 171 females) observed for 282 553 patient years. There were 376 breast cancers, 66 endometrial cancers, and 44 ovarian cancers. The total number of cancers observed was less than that expected, with SIRs of 0.76 (95% CI: 0.69, 0.85) for breast cancer, 0.71 (95% CI: 0.55, 0.91) for endometrial cancer, and 0.66 (95% CI: 0.49, 0.90) for ovarian cancer.

Conclusions:

  Data strongly support a decreased risk of breast, ovarian, and endometrial cancers in SLE. This may be due to inherent differences in women in SLE (vs the general population) regarding endogenous oestrogen, other medications, and/or genetic make-up.

Oncology - Interpreting Clinical Trial Results - Clinical Options in Practice

Note: requires registration (free); worth reading

Oncology - Interpreting Clinical Trial Results

Authors: Maurie Markman, MD (More Info)

Released: 11/17/10

Last Reviewed: 12/1/10

(media) Regina: Pilot project tracks whether lab tests ordered by RQHR doctors are necessary (CA125)

Genetic variants associated with breast-cancer risk : The Lancet Oncology (Steven A Narod)

Note: register (free) to view

EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis - Journal of Clinical Pathology

EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis

"....Tumour tissues, such as primary and metastatic breast cancer, frequently overexpress EpCAM.2 Gastl and colleagues observed EpCAM overexpression in 35.6% of patients with invasive breast cancer, and this was associated with poor disease-free and overall survival.3 Moreover, our group has shown that survival decreases significantly with increasing amounts of EpCAM expression.4 EpCAM can be used as prognostic marker in node-positive and node-negative breast cancer.5 Furthermore, frequent and high-level EpCAM expression has been found in adenocarcinomas of the colon, stomach, pancreas and prostate.6 Most soft-tissue tumours and all lymphomas are EpCAM negative. EpCAM overexpression has been associated with a dismal prognosis in other tumour entities, such as gallbladder cancer,7 ovarian cancer8 and pancreatic cancer.9"

See also 
Table 3

EpCAM expression in genitourinary tract cancers (eg: ovarian, clear cell, mucinous...)

Conclusion
EpCAM expression was detected on adenocarcinomas of various primary sites. If EpCAM-specific antibodies are intended to be used in patients with cancer, we recommend prior immunohistochemical evaluation of EpCAM expression, particularly in patients with renal cell cancer, hepatocellular carcinoma, urothelial carcinoma, breast cancer and squamous cell carcinomas.

Apr 2011: Postherpetic Neuralgia: An Overview of the Pathophysiology, Presentation, and Management (shingles)

Postherpetic neuralgia (PHN) presents itself as a frustrating and fascinating subject within the realm of neuropathic pain. With herpes zoster (shingles) affecting roughly 3.4 per 1,000 people, and nearly .49 per 1,000 people developing PHN annually, the subject continues to be a prevalent dilemma in want of further study. Drs. Christopher Gharibo and Carolyn Kim explore the diagnosis, treatment and management of this complicated condition.

Download to read this article in PDF document:
Postherpetic Neuralgia: An Overview of the Pathophysiology, Presentation, and Management

This article is in PDF format and it requires Abobe Reader.

Apr 2011 Gastroenterology & Endoscopy News - Henry Lynch, MD, Delivers Keynote Address on Lynch Syndrome & Gary H. Hoffman, MD

Note: requires registration (free) to view, discusses sporadic cancer/s, BRAF mutation plus EPCAM mutations, treatment responses etc:

"EPCAM mutation carriers may have phenotypic features that differ from carriers of MSH2 mutations, namely, an almost exclusive expression of site-specific CRC and an absence of extracolonic cancers. “This is really new, and more information is needed on this,” he said".
"Of therapeutic interest, patients with MSI-high tumors may respond differently to chemotherapy."

 ----------------------------------------------------------------

"Henry Lynch, MD, Delivers Keynote Address on Lynch Syndrome

Doctor Who First Described the Syndrome Offers Guidance on Management of Inherited CRC

by Caroline Helwick

San Francisco—Microsatellite instability (MSI) is an important factor in the evaluation of Lynch syndrome colorectal cancer (CRC) and should be part of the workup of these patients, according to Henry Lynch, MD, who defined the syndrome and gave the keynote lecture at the 2011 American Society of Clinical Oncology Gastrointestinal Cancers Symposium....."

handbook (patient/consumer friendly) Australia: Understanding Genetic Tests for Lynch Syndrome - Information & Decision Aids

abstrract: A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas

Source

Department of Pathology, Stanford University, Stanford, CA, USA.

Abstract

Mismatch repair protein immunohistochemistry is a widely used method for detecting patients at risk for Lynch syndrome. Recent data suggest that a two-antibody panel approach using PMS2 and MSH6 is an effective screening protocol for colorectal carcinoma, but there are limited data concerning this approach for extraintestinal tumors.

blog's status: top five sites; pages view (#'s)

Top Five:

1)  Empathy - ASCO Connection -Physician BlogView - AS... 2)  Cochrane Review: abstract - Ultra-radical (extensi... 3)  PR-USA - Immunovaccine Reports Positive Interim Da... 4)  eMJA: The Easter bunny and the chocolate conspirac... 5)  Annual Report Card on Cancer in Canada(TM) reveals...     Pageviews yesterday 365 Pageviews last month 7,088

JNCI extract: Radiologists Urge FDA To Accept PET-Based Tumor Response Criteria in Clinical Trials

(U.S.) FDA Considers New Rules to Speed Up Confirmatory Trials of Cancer Drugs Granted Accelerated Approval

Spring 2011 Cure Magazine/website - "Take Our Poll' - chemobrain

Note: see very top of website page and click on 'take our poll' - a yes/no response
--------------------------------------------------------------
Take Our Poll

Do you believe you developed chemobrain due to cancer and/or treatment?

Search Sessions ASCO Advanced Planner annual meeting

Revisiting the Women’s Health Initiative Estrogen-Alone Trial - hcp.obgyn.net

Note: scroll to bottom for addition references

Towards fundamental research contribution in cancer survivorships | Patient's Section - defining life after cancer (physician response)

April 18th, 2011

Towards fundamental research contribution in cancer survivorships

We asked our Current Oncology Section Editors how they would define the term “life after cancer” and how that theme presents itself in their chosen fields. Below is a response from Dr. Michel L. Tremblay, Director of the Goodman Cancer Research Centre at McGill University: (cont'd)

abstract: Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations

"...Therefore, the Breast International Group and North American Breast Cancer Group have joined efforts to develop an International Male Breast Cancer Program and to pool epidemiologic data, clinical information, and tumor specimens. This international collaboration will also facilitate the future planning of clinical trials that can address essential questions in the treatment of male breast cancer."

Markman: KRAS Mutations in Ovarian Cancer -- Maybe Not

press release: Decoding cancer patients' genomes is powerful diagnostic tool (and potential treatments)

NBOCC News - April 2011 - National Breast and Ovarian Cancer Centre (NBOCC)

In this issue...

• National Breast and Ovarian Cancer Centre releases Reconciliation Action Plan
• Clinical practice guidelines for external review
• Promoting multidisciplinary care for all patients with cancer
• Shared care demonstration project update
• Virtual classrooms for rural health professionals caring for women with breast cancer
• NBOCC’s topic-specific clinical practice guidelines available in new online format
• Associate Professor John Buckingham
• New issue Clinical Update -Breast cancer: Issue 39

abstract: Familial Risks in Cancer of Unknown Primary: Tracking the Primary Sites

Conclusion:

The present data show that CUP is not a disease of random metastatic cancers but, instead, a disease of a defined set of cancers. The association of CUP with families of kidney, lung, and colorectal cancers suggests a marked genetic basis and shared metastatic mechanisms by many cancer types. Familial sites shared by CUP generally match those arising in tissue-of-origin determinations and, hence, suggest sites of origin for CUP. Mechanistic exploration of CUP may provide insight into defense against primary tumors and the metastatic process.

abstract: A putative Lynch syndrome family carrying MSH2 and MSH6 variants of uncertain significance—functional analysis reveals the pathogenic one (

Abstract

Inherited pathogenic mutations in the mismatch repair (MMR) genes, MSH2, MLH1, MSH6, and PMS2 predispose to Lynch syndrome (LS). However, the finding of a variant or variants of uncertain significance (VUS) in affected family members complicates the risk assessment. Here, we describe a putative LS family carrying VUS in both MSH2 (c.2768T>A, p.Val923Glu) and MSH6 (c.3563G>A, p.Ser1188Asn). Two colorectal cancer (CRC) patients were studied for mutations and identified as carriers of both variants. In spite of a relatively high mean age of cancer onset (59.5 years) in the family, many CRC patients and the tumor pathological data suggested that the missense variation in MSH2, the more common susceptibility gene in LS, would be the predisposing alteration. However, MSH2 VUS was surprisingly found to be MMR proficient in an in vitro MMR assay and a tolerant alteration in silico. By supplying evidence that instead of MSH2 p.Val923Glu the MSH6 p.Ser1188Asn variant is completely MMR-deficient, the present study confirms the previous findings, and suggests that MSH6 (c.3563G>A, p.Ser1188Asn) is the pathogenic mutation in the family. Moreover, our results strongly support the strategy to functionally assess all identified VUS before predictive gene testing and genetic counseling are offered to a family.

free full access: Understanding the Estrogen Receptor–Positive Breast Cancer Genome: Not Even the End of the Beginning

Ottawa press release: (drug GAP-107B8 / ascites) PharmaGap Sees Positive Results from In Vivo Ovarian Cancer Models at the Ottawa Hospital Research Institute

Note: in research  

OTTAWA, ONTARIO--(Marketwire - April 18, 2011) - PharmaGap Inc. (TSX VENTURE:GAP)(OTCBB:PHRGF) ("PharmaGap" or "the Company") today announced initial results from preclinical testing at the Ottawa Hospital Research Institute ("OHRI"). Initial results from this study are positive and provide evidence that a peptide formulation of PharmaGap's lead cancer drug GAP-107B8 administered via the intraperitoneal route can reduce tumour burden (19%) and significantly suppress ascites formation (73%) relative to controls. The test was undertaken at OHRI in collaboration with Dr. Barbara Vanderhyden. Dr. Vanderhyden, upon initial review of the data commented "The reduction in ascites volume is very interesting in its own right, because this is a notable cause of morbidity in women with ovarian cancer. There is currently no drug therapy that is effective against ovarian cancer-associated ascites accumulation. Paracentesis, the removal of abdominal ascites, is commonly used to alleviate symptoms and prolong survival of women with ovarian cancer.......

.........In this study two formulations of GAP-107B8 peptides were tested in an established intraperitoneal xenograft model in immune-deficient mice and evaluated for tumour burden and accumulation of malignant ascites (excess fluid containing cancer cells in the abdominal cavity). The cell line selected for testing (OCC-1 human ovarian cancer) is of a phenotype characterized by the production of peritoneal ascites with growth of multiple small solid tumours......

(adverse events) FDA: Safety Alerts for Human Medical Products > Axxent FlexiShield Mini by iCAD (formerly Xoft Inc.): Recall- Product May Shed Particles of Tungsten (breast)

RECOMMENDATION: Customers were instructed to stop using all units of the Flexishield Mini Catalog Number F5300 in their inventory and return them to the company. It is recommended that health care professionals inform the patient about the likelihood of post-operative tungsten particles in the breast and continue the imaging recommended in your clinical protocol for the full 5 years, unless otherwise directed by the patient’s treatment team. For the recalled lot numbers and additional recommendations please see the Recall Notice.
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

• Complete and submit the report Online: www.fda.gov/MedWatch/report.htm

WebMD article: DNR Orders May Affect Surgical Outcomes (note: article source Archives of Surgery media release)

"If someone says, 'If my heart stops, I don't want it to be restarted,' that is one thing, but if they say something broad like, 'I don't want you to use extreme measures,' What do extreme measures mean? I think that is fuzzier," says Roman.
"It is important to have the conversation in more detail between physician and patient," says Roman. "So physicians can understand their patients' wishes better, and the patient understands the risks and outcomes better by knowing what to expect if certain things happen.".....

View Article Sources

SOURCES:
Roman, S. Archives of Surgery, April 18, 2011, advance online edition.
Clarence Braddock, MD, MPH, professor of medicine and associate dean for medical education, Stanford School of Medicine; director of clinical ethics, Stanford Center for Biomedical Ethics.
J. Randall Curtis, MD, MPH, section head of pulmonary and critical care medicine, Harborview Medical Center; professor of medicine, University of Washington, Seattle.
News release, American Medical Association.

abstract:
ONLINE FIRST
High Mortality in Surgical Patients With Do-Not-Resuscitate Orders
Analysis of 8256 Patients

What did these pharma marketers think they were going to hear by inviting bioethicist Carl Elliott? - Gary Schwitzer's HealthNewsReview Blog

What did these pharma marketers think they were going to hear by inviting bioethicist Carl Elliott?

By Gary Schwitzer on April 12, 2011 2:50 PM 
 

The DTC (direct to consumer) National Conference ("The Forum for DTC Thought Leaders") invited tough-talking, straight-shooting bioethicist Carl Elliott to speak this year.


Then, at least according to this account, some didn't like "the feeling" that he imparted.


Scroll down to "Day One - Afternoon." If you didn't want to hear that "everything is broken - our government, our healthcare system, and the clinical trials side of the industry," then maybe Elliott was not the guy to invite.


Health care journalists who haven't had the opportunity to meet Elliott can do so this weekend at the Association of Health Care Journalists conference in Philadelphia, where he'll be on a panel, "Clinical trials: Intersection of ethical, practical and financial." Hint: If you don't want to hear what's broken, don't come.

Observations after 5 years and 1,500 stories on HealthNewsReview.org (see note patients/consumers)

Note: these questions/considerations may be valuable for patients/consumers as well as the intended focus which is media/stories such as (read the blog for more):

"Getting caught up in reporting on the latest study without reporting on larger, better-designed studies that have been done already (one recent story failed to mention that a recent Cochrane review had examined 106 papers on the same topic!)"

New Patient Safety Initiative Stresses Teamwork, Not Blame - Dr Berwick/Medscape "Doing It Right Costs Less Than Doing It Wrong"

"....Both Dr. Berwick and Sebelius said that the new program works hand in hand with the new healthcare act  (U.S.) , which measures and pays for the kind of high-quality, coordinated care envisioned in the initiative. In addition, similar to the Affordable Care Act, Partnership for Patients addresses the problem of runaway healthcare costs.

"The options are either to cut care or improve care," said Dr. Berwick. "I'm against cutting. I'm for improving. Doing [healthcare] right costs less than doing it wrong."

For more information about Partnership for Patients, visit the HHS Web site.

MJA Insight: : The cost of negligent opinion (expert opinion) WHAT should happen if an expert witness is negligent?

MJA Insight: Research doesn’t match cancer burden

"....Professor Young suggested that the National Health and Medical Research Council (NHMRC) could prioritise funding for specific cancers. “The NHMRC needs to take a more strategic view as to where they place the funds, and where they create the incentive for specific cancers,” he said.

He said this would encourage researchers to study the underrepresented cancers. “In my view, researchers go to where they can get the money and not necessarily to where the problems are, and I think this paper proves that,” he said...."
  
Dr Annette Katelaris:
"... the National Cancer Institute in the United States is planning to create a “cross-disease panel” that will establish priorities for funding and coordination of clinical trials."

Comment
	Jane McCredie: Answering the tricky question FULL STORY.
	Nick Graves: The real cost of research cuts FULL STORY.
	Dr Annette Katelaris: Matching funding to need FULL STORY.

The Oncologist - Complimentary access now available!

Note: The Oncologist has some very good articles/worthwhile spending time searching for items of interest, all typically written in 'plain english'

Complimentary access now available!

Trastuzumab (Herceptin) Beyond Progression in Retrospective Analyses: An Issue of Equal Opportunities -- The Oncologist

Note: Trastuzumab is also known as Herceptin "Based on these considerations, it would be interesting if Extra and colleagues could reanalyze their data by distinguishing patients stopping trastuzumab according to whether or not they had "equal opportunities" to patients continuing trastuzumab beyond progression." (The Oncologist) Editor's note: Dr. Extra was invited to reply but declined comment.

Pain in Underserved Community-Dwelling Chinese American Cancer Patients: Demographic and Medical Correlates --- The Oncologist

Note: registration is free/access

eMJA: The Easter bunny and the chocolate conspiracy

abstract: eMJA: Doctors breaching patient privacy: Orwell redux

eMJA: Editorial: Alerting genetic relatives to a risk of serious inherited disease without a patient’s consent

Canada: Gynecologic Cancer Conference: Creating Collaborative Care - Agenda | Online Registration by Cvent

PR-USA - Immunovaccine Reports Positive Interim Data from Phase I Clinical Trial of DPX-0907 in Patients With Ovarian Cancer

"....The ongoing Phase I clinical trial of DPX-0907 is an open-label, dose-escalating evaluation of the vaccine's safety and tolerability in patients with advanced breast, ovarian or prostate cancer. Immunovaccine developed DPX-0907 with seven peptide antigens designed to target multiple cancer pathways.
Enrollment in the study has been completed. This preliminary evaluation examined vaccine responses in the first fifteen patients enrolled in the study; three with breast cancer, five with ovarian cancer and seven with prostate cancer. Immunovaccine will perform a more detailed analysis of samples collected from all patients by Q3 2011. Patients received three injections (0.25 mL or 1 mL) of the active immune therapy DPX-0907........"

press release: Experimental drug (NVP-BEZ235) inhibits cell signaling pathway and slows ovarian cancer growth

Note: in research

The study, performed on cells lines and mouse models, appears in the April 15, 2011 issue of the journal Clinical Cancer Research.

article - included comments:

'The experimental drug is being tested as a single agent at the Jonsson Cancer Center in human clinical trials against other solid tumors. Researchers involved with those studies have said early results are encouraging.
"This is clearly a promising agent with activity in humans," said Dr. John Glaspy, a professor of hematology/oncology and a Jonsson Cancer Center scientist involved with the studies. "We are still assessing its tolerability in patients."
Dorigo said he hopes to initiate a clinical trial for women with ovarian cancer that tests the combination of NVP-BEZ235 with platinum chemotherapy, as he believes that the combination might be more effective than each drug alone."

Annual Report Card on Cancer in Canada(TM) reveals canadians fighting cancer on two fronts: the disease and the system

Annual Report Card on Cancer in Canada(TM) reveals canadians fighting cancer on two fronts: the disease and the system Cancer Advocacy Coalition of Canada Provides New Insights into Current Cancer Landscape
Toronto, April 13, 2011 - The Cancer Advocacy Coalition of Canada (CACC) reveals in its 2010-2011 Report Card on Cancer in Canada that the current roadmap for cancer care in this country presents patients with numerous unnecessary barriers to accessing the care and support they need, from prevention programs, to timely diagnostics and access to treatment. At a time when they are at their weakest and most vulnerable, too often Canadian cancer patients are forced to fight not only their disease, but the healthcare system as whole, making an already complex and challenging journey even harder.....

For more information, or to view and download the 2010-2011 Report Card on Cancer in Canada, visit the CACC's website at www.canceradvocacy.ca.

Medical errors in the USA: human or systemic? : The Lancet

Medical errors in the USA: human or systemic? : The Lancet

Cochrane Review: abstract - Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian can

Note:  this blogger participated as a consumer reviewer

Abstract

BACKGROUND: Ovarian cancer is the sixth most common cancer among women and the leading cause of death in women with gynaecological malignancies. Opinions differ regarding the role of ultra-radical (extensive) cytoreductive surgery in ovarian cancer treatment.

OBJECTIVES: To evaluate the effectiveness and morbidity associated with ultra-radical/extensive surgery in the management of advanced stage ovarian cancer.


MAIN RESULTS: One non-randomised study met our inclusion criteria. It analysed retrospective data for 194 women with stage IIIC advanced epithelial ovarian cancer who underwent either ultra-radical (extensive) or standard surgery and reported disease specific overall survival and perioperative mortality. Multivariate analysis, adjusted for prognostic factors, identified better disease specific survival among women receiving ultra-radical surgery, although this was not statistically significant (Hazard ratio (HR) = 0.64, 95% confidence interval (CI): 0.40 to 1.04). In a subset of 144 women with carcinomatosis, those who underwent ultra-radical surgery had significantly better disease specific survival than women who underwent standard surgery (adjusted HR = 0.64, 95% CI 0.41 to 0.98). Progression-free survival and quality of life (QoL) were not reported and adverse events were incompletely documented. The study was at high risk of bias.

AUTHORS' CONCLUSIONS: We found only low quality evidence comparing ultra-radical and standard surgery in women with advanced ovarian cancer and carcinomatosis. The evidence suggested that ultra-radical surgery may result in better survival. It was unclear whether there were any differences in progression-free survival, QoL and morbidity between the two groups. The cost-effectiveness of this intervention has not been investigated. We are, therefore, unable to reach definite conclusions about the relative benefits and adverse effects of the two types of surgery.In order to determine the role of ultra-radical surgery in the management of advanced stage ovarian cancer, a sufficiently powered randomised controlled trial comparing ultra-radical and standard surgery or well-designed non-randomised studies would be required.

Empathy - ASCO Connection -Physician BlogView - ASCO Connection Blogs - Robert Miller, MD

Note: physician blog regarding NY Times article and empathy. (Many oncologists have probably been following Dr. Peter Bach’s moving and beautifully written series, recently concluded in the New York Times)


......Hearing the patient’s voice directly without health provider filtering is a small step toward minimizing traditional barriers to empathy. And I would have to believe that appreciating the psychosocial aspects of the patient’s cancer experience is the area that needs the most work for providers. I know that for my own practice and interactions with patients, I am probably decent at understanding physical toxicities – not that I can’t do a better job any given day. But I am sure I do far less well at understanding the true impact their cancer has on the things that I don’t see, like what happens when they go home and try to deal with the pressures of child care, trying to function at work while battling treatment-related fatigue, and agonizing over the financial impact of their cancer on their daily lives........